Márcio Nehemy, MD, PhD, Erika Magalhães, MD, PhD, Patrícia Nehemy, MD


To evaluate photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP).


Thirty eight eyes of thrity one consecutive patients with RAP were treated with PDT. Fifteen of these eyes received also an intravitreous injection of triancinolone acetonide (4 mg). Eyes with a hot spot outside the fovea as shown by indocyanine green videoangiography (ICG) were treated by green laser and were excluded. Eyes with visual acuity (VA) worse than 20/400 were also excluded. The patients were evaluated each three months by fluorescein angiography (FA) and optical coherence tomography (OCT). The mean follow-up was 10 months.


Thirty eyes were evaluated at three months. In 9 eyes (30%) the VA improved (one or more lines); in 11 (37%) the VA was the same and in 10 eyes (33%) the VA decreased (one or more lines). From 20 eyes evaluated at six months, the VA improved in 8 eyes (40%), was stable in 4 (20%) and decreased in 8 (40%). At 12 months, the VA improved in 3 eyes (18%), was stable in 5 (29%) and decreased in 9 (53%). The number of treatments per patient ranged from 1 to 5 treatments. There was a correlation between the anatomic and functional results.


PDT can be useful for treatment of selected cases of RAP.

Take-home message:

PDT may have a role in the management of selected cases of Retinal Angiomatous Proliferation.